中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2010年
8期
815-817
,共3页
王景斌%仝峰%张颖%杨琴
王景斌%仝峰%張穎%楊琴
왕경빈%동봉%장영%양금
急性心肌梗死%瑞舒伐他汀%经皮冠状动脉介入治疗%炎性因子%内皮功能
急性心肌梗死%瑞舒伐他汀%經皮冠狀動脈介入治療%炎性因子%內皮功能
급성심기경사%서서벌타정%경피관상동맥개입치료%염성인자%내피공능
Myocardial infarction%Rosuvastatin%Percutaneous coronary intervention%Inflammatory factor%Endothelial function
目的 观察瑞舒伐他汀对急性心肌梗死(AMI)患者经皮冠状动脉介入治疗(PCI)后炎性因子和血管内皮功能的影响.方法 78例AMI患者均行冠状动脉造影及PCI治疗,术后分为对照组38例和瑞舒伐他汀组40例.2组患者均常规使用硝酸酯类、低分子肝素钙、阿司匹林、氯吡格雷.瑞舒伐他汀组在常规用药基础上加服瑞舒伐他汀10 mg/次,每日1次.2组均连续用药6个月.记录所有患者出院后6个月内心血管事件,检测血脂、炎症相关生物标志物和血管内皮功能.结果 出院后6个月内瑞舒伐他汀组心血管事件发生率(5.0%)显著低于对照组(18.4%),差异有统计学意义(χ2=4.52,P<0.05);6个月后瑞舒伐他汀组甘油三酯(TG)、胆固醇(TC)、白细胞介素-6(IL-6)、超敏C-反应蛋白(hs-CRP)、内皮素-1(ET-1)及氧化低密度脂蛋白(ox-LDL)[(2.15±0.54)mmol/L;(4.16±0.28)mmol/L;(6.80±2.65)ng/L;(4.02±1.58)mg/L;(62.45±9.38)ng/L;381.65±39.73]比对照组((2.47±0.59)mmolL;(5.29±0.31)mmol/L:(9.39±4.17)ng/L;(5.76±1.52)mg/L;(81.75±10.23)ng/L;485.91±42.68]显著降低(t值分别为2.423、16.910、3.291、4.952、8.691、11.173,P均<0.01);瑞舒伐他汀组血一氧化氮(62.17±17.69)μmoL/L比对照组(48.27±18.35)μmol/L显著升高(t=3.406,P<0.01).瑞舒伐他汀组未发现严重的不良反应.结论 瑞舒伐他汀可减轻AMI患者PCI术后炎性反应,改善血管内皮功能,且不良反应少.
目的 觀察瑞舒伐他汀對急性心肌梗死(AMI)患者經皮冠狀動脈介入治療(PCI)後炎性因子和血管內皮功能的影響.方法 78例AMI患者均行冠狀動脈造影及PCI治療,術後分為對照組38例和瑞舒伐他汀組40例.2組患者均常規使用硝痠酯類、低分子肝素鈣、阿司匹林、氯吡格雷.瑞舒伐他汀組在常規用藥基礎上加服瑞舒伐他汀10 mg/次,每日1次.2組均連續用藥6箇月.記錄所有患者齣院後6箇月內心血管事件,檢測血脂、炎癥相關生物標誌物和血管內皮功能.結果 齣院後6箇月內瑞舒伐他汀組心血管事件髮生率(5.0%)顯著低于對照組(18.4%),差異有統計學意義(χ2=4.52,P<0.05);6箇月後瑞舒伐他汀組甘油三酯(TG)、膽固醇(TC)、白細胞介素-6(IL-6)、超敏C-反應蛋白(hs-CRP)、內皮素-1(ET-1)及氧化低密度脂蛋白(ox-LDL)[(2.15±0.54)mmol/L;(4.16±0.28)mmol/L;(6.80±2.65)ng/L;(4.02±1.58)mg/L;(62.45±9.38)ng/L;381.65±39.73]比對照組((2.47±0.59)mmolL;(5.29±0.31)mmol/L:(9.39±4.17)ng/L;(5.76±1.52)mg/L;(81.75±10.23)ng/L;485.91±42.68]顯著降低(t值分彆為2.423、16.910、3.291、4.952、8.691、11.173,P均<0.01);瑞舒伐他汀組血一氧化氮(62.17±17.69)μmoL/L比對照組(48.27±18.35)μmol/L顯著升高(t=3.406,P<0.01).瑞舒伐他汀組未髮現嚴重的不良反應.結論 瑞舒伐他汀可減輕AMI患者PCI術後炎性反應,改善血管內皮功能,且不良反應少.
목적 관찰서서벌타정대급성심기경사(AMI)환자경피관상동맥개입치료(PCI)후염성인자화혈관내피공능적영향.방법 78례AMI환자균행관상동맥조영급PCI치료,술후분위대조조38례화서서벌타정조40례.2조환자균상규사용초산지류、저분자간소개、아사필림、록필격뢰.서서벌타정조재상규용약기출상가복서서벌타정10 mg/차,매일1차.2조균련속용약6개월.기록소유환자출원후6개월내심혈관사건,검측혈지、염증상관생물표지물화혈관내피공능.결과 출원후6개월내서서벌타정조심혈관사건발생솔(5.0%)현저저우대조조(18.4%),차이유통계학의의(χ2=4.52,P<0.05);6개월후서서벌타정조감유삼지(TG)、담고순(TC)、백세포개소-6(IL-6)、초민C-반응단백(hs-CRP)、내피소-1(ET-1)급양화저밀도지단백(ox-LDL)[(2.15±0.54)mmol/L;(4.16±0.28)mmol/L;(6.80±2.65)ng/L;(4.02±1.58)mg/L;(62.45±9.38)ng/L;381.65±39.73]비대조조((2.47±0.59)mmolL;(5.29±0.31)mmol/L:(9.39±4.17)ng/L;(5.76±1.52)mg/L;(81.75±10.23)ng/L;485.91±42.68]현저강저(t치분별위2.423、16.910、3.291、4.952、8.691、11.173,P균<0.01);서서벌타정조혈일양화담(62.17±17.69)μmoL/L비대조조(48.27±18.35)μmol/L현저승고(t=3.406,P<0.01).서서벌타정조미발현엄중적불량반응.결론 서서벌타정가감경AMI환자PCI술후염성반응,개선혈관내피공능,차불량반응소.
Objective To observe the effect of Rosuvastatin on the function of vascular endothelial and inflammatory response in patients with acute myocardial infarction ( AMI) after intervention. Methods Seventy-eight patients with AMI patients underwent coronary angiography and PCI treatment The patients were divided into the control group (38 patients) and the Rosuvastatin group (40 patients) after PCI treatment All patients were routinely used nitrates, low molecular weight heparin,aspirin,clopidogrel,the Rosuvastatin group were treated on the basis of conventional medication plus service Rosuvastatin 10 mg/time, once a day. Both groups were continuous medicated for 6 months. Cardiovascular events of all patients, the serum lipids, inflammation-related biomarkers and indicators of vascular endothelial function were followed up for 6 months after discharge. Results The cardiovascular events in the Rosuvastatin group (5. 0% ) was significantly lower than that of the control group (18.4%) after discharge within 6 months (χ2 = 4. 52, P < 0. 05). After 6 months of discharge, the serum lipids, the serum IL-6, hs-CRP,plasma ET-1 and ox-LDL of Rosuvastatin group ((2. 16 ±0. 54)mmol/L,(4. 16 ±0. 28)mmol/L,(6. 80 ± 2. 65) ng/L, (4. 02 ± 1. 58) mg/L, ( 62. 45 ± 9. 38) ng/L and 381. 65 ± 39. 73, respectively) was significantly lower than those of the control group ((2.47 ±0. 59) mmol/L, (5. 29 ±0. 31 )mmol/L, (9. 39 ±4. 17) ng/L, (5. 76 ± 1. 52)ng/L, (81. 75 ± 10. 23) ng/L and 485. 91 ±42. 68,respectively) (t =2. 423,16. 910,3. 291,4. 952,8. 691 and 11. 173 , respectively , P <0. 01 ). The serum NO of Rosuvastatin group ( ( 62. 17 ± 17. 69 ) μmol/L) was significantly higher than than that of the control group ( (48. 27 ±18. 35 ) μmol/L) (t = 3.406, P < 0.01 ) . The serious adverse events were not observed in the Rosuvastatin group. Conclusions Rosuvastatin reduces inflammatory reaction after PCI in patients with AMI, improves endothelial function, and reduces adverse reactions.
